The brain-penetrant cell-cycle inhibitor p28 sensitizes brain metastases to DNA-damaging agents

Abstract Background Brain metastases (BMs), the most common tumors of the central nervous system, are life-threatening with a dismal prognosis. The major challenges to developing effective treatments for BMs are the limited abilities of drugs to target tumors and to cross the blood-brain barrier (BBB). We aimed to investigate the efficacy of our therapeutic approach against BMs in mouse models that recapitulate the clinical manifestations of BMs. Methods BMs mouse models were constructed by injecting human breast, lung cancer, and melanoma intracardially, which allowed the BBB to remain intact. We investigated the ability of the cell-penetrating peptide p28 to cross the BBB in an in vitro 3D model and in the BMs animal models. The therapeutic effects of p28 in combination with DNA-damaging agents (radiation and temozolomide) on BMs were also evaluated. Results p28 crossed the intact BBB more efficiently than the standard chemotherapeutic agent, temozolomide. Upon crossing the BBB, p28 localized preferentially to tumor lesions and enhanced the efficacy of DNA-damaging agents by activating the p53-p21 axis. In the BMs animal models, radiation in combination with p28 significantly reduced the tumor burden of BMs. Conclusions The cell-cycle inhibitor p28 can cross the BBB localize to tumor lesions in the brain and enhance the inhibitory effects of DNA-damaging agents on BMs, suggesting the potential therapeutic benefits of this molecule in BMs.

[1]  A. Chakrabarty,et al.  Cross-talk between cancer and Pseudomonas aeruginosa mediates tumor suppression , 2023, Communications Biology.

[2]  P. Brown,et al.  Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Shilkaitis,et al.  Nontoxic Tumor-Targeting Optical Agents for Intraoperative Breast Tumor Imaging. , 2022, Journal of medicinal chemistry.

[4]  Mohd Nazmul Hasan Apu,et al.  Multi-omics analysis predicts fibronectin 1 as a prognostic biomarker in glioblastoma multiforme. , 2022, Genomics.

[5]  F. Heppner,et al.  Decoding molecular programs in melanoma brain metastases , 2022, Nature Communications.

[6]  A. Shilkaitis,et al.  Image-guided surgery with a new tumour-targeting probe improves the identification of positive margins , 2022, EBioMedicine.

[7]  S. Nah,et al.  Triculture Model of In Vitro BBB and its Application to Study BBB‐Associated Chemosensitivity and Drug Delivery in Glioblastoma , 2021, Advanced Functional Materials.

[8]  L. Cucullo,et al.  A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity , 2020, Fluids and barriers of the CNS.

[9]  P. Brown,et al.  Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Powell,et al.  Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging. , 2020, Journal of visualized experiments : JoVE.

[11]  H. Friedman,et al.  Management of glioblastoma: State of the art and future directions. , 2020, CA: a cancer journal for clinicians.

[12]  J. Lahann,et al.  Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy , 2019, Nature Communications.

[13]  Lin-Ping Wu,et al.  Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide , 2019, Nature Communications.

[14]  J. Ježek,et al.  Mitochondrial translocation of cyclin C stimulates intrinsic apoptosis through Bax recruitment , 2019, EMBO reports.

[15]  C. Ireson,et al.  The role of mouse tumour models in the discovery and development of anticancer drugs , 2019, British Journal of Cancer.

[16]  J. Poyet,et al.  Recent Advances in Cell Penetrating Peptide-Based Anticancer Therapies , 2019, Molecules.

[17]  Giles W. Robinson,et al.  Challenges to curing primary brain tumours , 2019, Nature Reviews Clinical Oncology.

[18]  K. Aldape,et al.  Advances in multidisciplinary therapy for meningiomas. , 2019, Neuro-oncology.

[19]  Mark E. Davis,et al.  Method of establishing breast cancer brain metastases affects brain uptake and efficacy of targeted, therapeutic nanoparticles , 2018, Bioengineering & translational medicine.

[20]  V. Sawlani,et al.  The Expanding Role of Radiosurgery for Brain Metastases , 2018, Medicines.

[21]  Yuno Lee,et al.  Oligomer Formation Propensities of Dimeric Bundle Peptides Correlate with Cell Penetration Abilities , 2018, ACS central science.

[22]  F. Gosselet,et al.  Mimicking brain tissue binding in an in vitro model of the blood‐brain barrier illustrates differences between in vitro and in vivo methods for assessing the rate of brain penetration , 2018, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[23]  S. Cannistraro,et al.  Binding of Amphipathic Cell Penetrating Peptide p28 to Wild Type and Mutated p53 as studied by Raman, Atomic Force and Surface Plasmon Resonance spectroscopies. , 2017, Biochimica et biophysica acta. General subjects.

[24]  I. Pollack,et al.  Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study. , 2016, Neuro-oncology.

[25]  Ernest Giralt,et al.  Blood-brain barrier shuttle peptides: an emerging paradigm for brain delivery. , 2016, Chemical Society reviews.

[26]  M. Ahluwalia,et al.  Targeted Therapy in Brain Metastases: Ready for Primetime? , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[27]  W. Wick,et al.  A malignant cellular network in gliomas: potential clinical implications. , 2016, Neuro-oncology.

[28]  P. Steeg,et al.  Targeting metastasis , 2016, Nature Reviews Cancer.

[29]  C. Beattie,et al.  p28-Mediated Activation of p53 in G2-M Phase of the Cell Cycle Enhances the Efficacy of DNA Damaging and Antimitotic Chemotherapy. , 2016, Cancer research.

[30]  W. Banks.  Peptides and the blood–brain barrier , 2015, Peptides.

[31]  D. Raucher,et al.  Cell-penetrating peptides: strategies for anticancer treatment. , 2015, Trends in molecular medicine.

[32]  Kwok-Kin Wong,et al.  Non-small-cell lung cancers: a heterogeneous set of diseases , 2014, Nature Reviews Cancer.

[33]  Manuel Hidalgo,et al.  Patient-derived xenograft models: an emerging platform for translational cancer research. , 2014, Cancer discovery.

[34]  M. Caffo,et al.  Patented nanomedicines for the treatment of brain tumors. , 2013, Pharmaceutical patent analyst.

[35]  D. Kirsch,et al.  Role of p53 in regulating tissue response to radiation by mechanisms independent of apoptosis. , 2013, Translational cancer research.

[36]  Donald W. Miller,et al.  Rapid and Reversible Enhancement of Blood–Brain Barrier Permeability Using Lysophosphatidic Acid , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[37]  S. B. Pehlivan.  Nanotechnology-Based Drug Delivery Systems for Targeting, Imaging and Diagnosis of Neurodegenerative Diseases , 2013, Pharmaceutical Research.

[38]  R. Muschel,et al.  Ultrasonography-guided intracardiac injection: an improvement for quantitative brain colonization assays. , 2013, The American journal of pathology.

[39]  S. Cannistraro,et al.  p28, A first in class peptide inhibitor of cop1 binding to p53 , 2013, British Journal of Cancer.

[40]  Xianghua Luo,et al.  The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer , 2013, Journal of Neuro-Oncology.

[41]  D. Majumdar,et al.  A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours , 2013, British Journal of Cancer.

[42]  H. Immervoll,et al.  In vivo animal models for studying brain metastasis: value and limitations , 2013, Clinical & Experimental Metastasis.

[43]  Meihua Wang,et al.  A nomogram for individualized estimation of survival among patients with brain metastasis. , 2012, Neuro-oncology.

[44]  L. Jia,et al.  Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination , 2011, Cancer Chemotherapy and Pharmacology.

[45]  D. Majumdar,et al.  A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt , 2011, Angiogenesis.

[46]  P. Steeg,et al.  Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer , 2010, Clinical Cancer Research.

[47]  J. Gallo,et al.  Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. , 2009, Neuro-oncology.

[48]  C. Beattie,et al.  Noncationic peptides obtained from azurin preferentially enter cancer cells. , 2009, Cancer research.

[49]  Xiaodong Wang,et al.  Formation of apoptosome is initiated by cytochrome c-induced dATP hydrolysis and subsequent nucleotide exchange on Apaf-1. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[50]  G. Failla,et al.  Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study. , 2005, Lung cancer.

[51]  A. Chakrabarty,et al.  Internalization of bacterial redox protein azurin in mammalian cells: entry domain and specificity , 2005, Cellular microbiology.

[52]  Wolfgang Löscher,et al.  Drug resistance in brain diseases and the role of drug efflux transporters , 2005, Nature Reviews Neuroscience.

[53]  Adrian L Harris,et al.  Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1 , 2005, Clinical Cancer Research.

[54]  I. Hidalgo,et al.  Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. , 2005, International journal of pharmaceutics.

[55]  C. L. Graff,et al.  Drug transport at the blood-brain barrier and the choroid plexus. , 2004, Current drug metabolism.

[56]  A. Gudkov,et al.  Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53 , 2003, Oncogene.

[57]  J. Kirkwood,et al.  Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. , 2000, The oncologist.

[58]  P. Kehrli,et al.  [Epidemiology of brain metastases]. , 1999, Neuro-Chirurgie.

[59]  H. Niitani,et al.  [Phase II study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[60]  S. Rauth,et al.  Establishment of a human melanoma cell line lacking p53 expression and spontaneously metastasizing in nude mice. , 1994, Anticancer research.

[61]  C. Bucana,et al.  Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. , 1992, The American journal of pathology.

[62]  C. Beattie,et al.  Human breast carcinoma cell lines: ultrastructural, genotypic, and immunocytochemical characterization. , 1992, Anticancer research.

[63]  Carl O. Pabo,et al.  Cellular uptake of the tat protein from human immunodeficiency virus , 1988, Cell.

[64]  H. Davson.  Blood–brain barrier , 1977, Nature.

[65]  E. De Carli,et al.  [Immunotherapy in brain tumors]. , 2017, Annales de pathologie.

[66]  Dihua Yu,et al.  Brain metastasis: Unique challenges and open opportunities. , 2017, Biochimica et biophysica acta. Reviews on cancer.

[67]  E. Hansson,et al.  Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.

[68]  R A Patchell,et al.  Brain metastases. , 1991, Neurologic clinics.

[69]  W. Y. Zhu.  [Peptides and the blood-brain barrier]. , 1987, Sheng li ke xue jin zhan [Progress in physiology].

[70]  J. Posner,et al.  Intracranial metastases from systemic cancer. , 1978, Advances in neurology.